Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens  by Daly, K. et al.
Geographical variation in serological responses to recombinant
Pneumocystis jirovecii major surface glycoprotein antigens
K. Daly1,2, J. Koch1,2, N. Respaldiza4,5, C. de la Horra4,5, M. A. Montes-Cano4,5, F. J. Medrano3,5, J. M. Varela3,5, E. J. Calderon3,5
and P. D. Walzer1,2
1) Department of Internal Medicine, Division of Infectious Diseases, University of Cincinnati, Cincinnati, 2) VA Medical Center, Cincinnati, OH, USA,
3) Department of Internal Medicine, 4) Institute of Biomedicine of Seville and 5) CIBER for Epidemiology and Public Health, Virgen del Rocio Hospital,
Seville, Spain
Abstract
The use of recombinant fragments of the major surface glycoprotein (Msg) of Pneumocystis jirovecii has proven useful for studying serolo-
gical immune responses of blood donors and human immunodeﬁciency virus (HIV)-positive (HIV+) patients. Here, we have used ELISA
to measure antibody titres to Msg fragments (MsgA, MsgB, MsgC1, MsgC3, MsgC8 and MsgC9) in sera isolated in the USA (n=200) and
Spain (n=326), to determine whether geographical location affects serological responses to these antigens. Blood donors from Seville
exhibited a signiﬁcantly greater antibody titre to MsgC8, and signiﬁcantly lower responses to MsgC3 and MsgC9, than did Cincinnati
(USA) donors. Spanish blood donors (n=162) also exhibited elevated responses to MsgC1, MsgC8 and MsgC9 as compared with Spanish
HIV+ (n=164) patients. HIV+ patients who had Pneumocystis pneumonia (PcP+) exhibited a higher response to MsgC8 than did HIV+
PcP) patients. These data show that geographical location plays a role in responsiveness to Msg fragments. Additionally, these fragments
have utility in differentiating HIV+ PcP and HIV+ PcP+ among patient populations.
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Introduction
Pneumocystis jirovecii is an opportunistic fungal pathogen of
humans that causes Pneumocystis pneumonia (PcP) in immu-
nocompromised individuals, including those infected with
human immunodeﬁciency virus (HIV) [1–4]. Effective drugs
for the treatment of PcP exist; however, the potential for
resistance to these therapies, together with the longer survi-
val of HIV-positive (HIV+) patients, due to antiviral therapies,
has spurred an interest in antigen-speciﬁc immunity to Pneu-
mocystis infection in HIV+ patients [5].
The role of antibodies in infection with P. jirovecii is not
well understood, but there is a high frequency of reactivity
to Pneumocystis antigens in healthy adults and children [6–
10]. Much work has focused on using animal models of PcP
infection, highlighting a potential role for antibodies in the
prevention of PcP [11–18].
The majority of immunological studies on reactivity to Pneu-
mocystis spp have used complex antigens derived from infected
animal lungs [7,9,19–22]. These preparations of antigens are
not well deﬁned, and there are many limitations to their use:
they contain many different antigens; the spectrum of variable
antigens such as the major surface glycoprotein (Msg) can vary
with the preparation; the absolute volume of a specimen is lim-
ited because, in the absence of an in vitro culture system, the
only source of organisms is infected host lung; and samples
may be contaminated with co-infecting pathogens. Taken
together, these problems suggest that the use of recombinant
antigens may be more appropriate for immunological studies.
Smulian et al. [9] used western blot to demonstrate
signiﬁcant geographical variation in serological responses to
high molecular weight antigens from rat-derived Pneumocystis
carinii in HIV-negative (HIV)) people from ﬁve global locations.
The nature of these antigens could not be determined in this
study, given that multiple proteins may co-migrate in electro-
phoresis, and many immunoreactive proteins have not been
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deﬁnitively identiﬁed. Given the limitations of using crude pre-
parations of antigen, it would be interesting to determine
whether the serological response to a single antigen exhibits
geographical variation. Such a study would require the use of
recombinant antigens to provide a clear answer.
We and others have started using recombinant fragments
of Msg to probe the immune responses of blood donors and
HIV+ patients [6,23–25]. Msg is a well-characterized antigen
that is encoded by a family of genes in the Pneumocystis gen-
ome, and only one Msg is expressed at a given time [12,26–
31], suggesting that the protein may have a role in immune
evasion. Msg has B-cell and T-cell epitopes, and can give pro-
tective immunity in some animal models [32–36]; however,
the relative roles of cell-mediated and humoral immunity to
Msg are not well understood.
We have recently examined the serological responses of
blood donors and HIV+ patients in the USA to three recombi-
nant fragments of Msg, which we called MsgA, MsgB, and
MsgC. Our work has focused mainly on MsgC, the C-termi-
nus of Msg, which is relatively conserved among different Msg
molecules, and can be recognized by human serum in western
blot and ELISA [24,25,37]. We have identiﬁed a panel of four
MsgC clones that differ from one another in putative amino
acid sequence. These clones behave differently from one
another in serological assays; for example, in ELISA, there is a
signiﬁcantly higher level of reactivity to MsgC1 and MsgC3,
but not to MsgC8 or MsgC9, in a cohort of HIV+ patients
who have had a previous bout of PcP as compared with either
the HIV+ PcP) patient group or blood donors. The frequency
of reactivity seen in western blot analysis also varies with the
Msg construct and the patient populations tested [37].
Here we have performed a study to address global reac-
tivity to a panel of recombinant Msg fragments and examined
the potential geographical variation in reactivity to these pro-
teins in ELISA. First, we examined blood donor sera isolated
in the USA and Spain for reactivity to recombinant Msg anti-
gens. Second, as antibody titres to Pneumocystis antigens have
been shown to vary with onset and recovery from PcP [38–
41], we tested HIV+ Spanish patients who did or did not
have PcP for reactivity to these recombinants, and compared
the results with those obtained for Spanish blood donors.
Materials and Methods
Serum specimens
The serum specimens used in this study came from the USA
and Spain. They included 200 samples from healthy blood
donors at the Hoxworth Blood Center, Cincinnati, OH,
USA, as well as 162 samples from blood donors and 164
samples from HIV+ patients, 29 of whom had PcP, at the
Virgen del Rocio University Hospital, Seville, Spain. PcP diag-
nosis was based on clinical data and microscopic examination
of respiratory samples (sputum or bronchoalveolar) using
immunoﬂuorescence with speciﬁc monoclonal antibodies
(Pneumo Cel IFA test; Cellabs, Brookvale, Australia).
Isolation and expression of Msg fragments
We have previously described the characterization of the Msg
fragments used in this study [24,25,37]. Brieﬂy, oligonucleo-
tides were designed on the basis of conserved sequences of
the known msg genes of P. jirovecii. These primers were used
in PCR, using DNA isolated from P. jirovecii-infected human
lung at autopsy or cloned msg genes as templates, and Ampli-
taq enzyme (Applied Biosystems, Foster City, CA, USA) to
generate msg gene segments. The PCR products were cloned
into the pET30 vector (Novagen, Madison, WI, USA) in the
correct orientation for expression in Escherichia coli. The
recombinant proteins were puriﬁed by afﬁnity chromatogra-
phy using HIS-binding resin (Novagen). The protein concen-
tration was determined by absorbance at 280 nm (A280 nm),
using a standard curve generated with bovine serum albumin.
ELISA
ELISA was performed similarly to previously reported proce-
dures [25]. Brieﬂy, the reactivity of each serum specimen to
Msg was corrected by subtraction of the reactivity of that
serum to phosphate-buffered saline (mean OD Msg – mean
OD phosphate-buffered saline). The results were quantitated
using a method similar to that of Bishop and Kovacs [23],
using a standard curve speciﬁc for each construct. Test sera
were assayed at dilutions that ﬁt the linear portion of the
standard curves, and units of reactivity were calculated. Sam-
ples whose values were below the standard curve were
assigned the lowest possible value of 1 U.
Statistics
Statistical analyses were performed using GraphPad Prism
(GraphPad Software, San Diego, CA, USA). Data were log
transformed to approximate normalcy, and statistical signiﬁ-
cance was calculated using either unpaired t-tests or
ANOVA (Kruskal–Wallis) with Dunn’s multiple-comparison
test. p-Values <0.05 were considered to be signiﬁcant.
Results
Reactivity in healthy blood donor sera
We ﬁrst compared 200 blood donor sera from Cincinnati
and 162 BD sera from Seville for reactivity to a panel of
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three recombinant Msg fragments that, together, span the full
length of Msg (MsgA, MsgB, and MsgC1 (Fig. 1). Similar to
our previously published ﬁndings [25,37], the overall reactiv-
ity to each of these three Msg fragments was low in the
healthy blood donor populations, with no signiﬁcant differ-
ences in the levels of reactivity to any of these constructs
between sera from Cincinnati and from Seville (Table 1).
To determine whether clonal variability had an effect on
reactivity of sera, we expanded the study to include three
MsgC clones that differ from MsgC1 and from one another
(Fig. 1) [37]. The magnitude of the responses to MsgC3,
MsgC8 and MsgC9 varied with the population studied. The
Cincinnati population exhibited higher responses than the
Seville population to both MsgC3 and MsgC9 (p <0.0001 and
p 0.035, respectively) (Table 1). However, the response to
MsgC8 was much greater in the donors from Seville (geo-
metric mean value of 22.27 U) than in the donors from Cin-
cinnati (geometric mean value of 3.42 U) (p <0.0001)
(Table 1).
Reactivity to Msg fragments in Spanish HIV+ patients
We had previously shown that HIV+ patients from Cincinnati
responded more strongly to MsgA, MsgB and MsgC1 than
did blood donors from Cincinnati [25]. We now tested 164
HIV+ patients from Seville for reactivity to each of the Msg
constructs, and compared the results with those obtained
for the blood donors from Seville. In contrast to our results
with US sera, the Spanish HIV+ patients had responses simi-
lar to or lower than those of blood donors from Spain. In
the Spanish population, blood donors had signiﬁcantly higher
responses than did HIV+ patients to MsgC1 (2.10 U and
1.11 U, respectively), MsgC8 (22.27 U and 8.59 U, respec-
tively), and MsgC9 (3.04 U and 1.33 U, respectively)
(p <0.0001 for all comparisons) (Table 2).
Seroreactivity to Msg fragments in HIV+ patients with or
without PcP
We have shown that HIV+ patients in Cincinnati who had a
prior bout of PcP responded more strongly to MsgC1 and
MsgC3 than did HIV+ patients who did not have PcP [37].
To determine whether any of the Msg constructs were use-
ful for differentiating between Spanish HIV+ patients on the
basis of prior PcP, the HIV+ patients who had PcP (n = 29)
were compared with those who did not (n = 135). With the
exception of the responses to MsgC8, there were no signiﬁ-
cant differences in the reactivity to any of the Msg constructs
between the PcP+ and PcP) HIV+ populations (Table 3). The
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FIG. 1. A schematic of the constructs used in this study. Major sur-
face glycoprotein (Msg)A, MsgB and MsgC span the length of Msg.
MsgC1, MsgC3, MsgC8 and MsgC9 are different clones of the C-ter-
minus of Msg.
TABLE 1. Geometric mean values and 95% CIs of ELISA by
blood donor and geographical location for each antigen
Antigen
Cincinnati
blood donors
(n = 200)
Seville
blood donors
(n = 162) p
MsgA 3.82 (2.99–4.886) 4.67 (3.65–5.96) 0.253
MsgB 1.81 (1.49–2.19) 1.84 (1.49–2.26) 0.911
MsgC1 2.05 (1.64–2.55) 2.10 (1.67–2.64) 0.883
MsgC3 4.42 (3.32–5.88) 1.90 (1.56–2.30) <0.0001
MsgC8 3.42 (2.62–4.45) 22.27 (17.06–29.04) <0.0001
MsgC9 4.70 (3.48–6.34) 3.04 (2.35–3.94) 0.035
TABLE 2. Geometric mean values and 95% CIs of ELISA by
blood donor and human immunodeﬁciency virus (HIV) sta-
tus for each antigen
Antigen
Seville blood
donors (n = 162)
Seville HIV+
patients
(n = 164) p
MsgA 4.67 (3.65–5.96) 3.58 (2.88–4.46) 0.113
MsgB 1.84 (1.49–2.26) 2.36 (1.89–2.93) 0.101
MsgC1 2.10 (1.67–2.64) 1.11 (1.01–1.22) <0.0001
MsgC3 1.90 (1.56–2.31) 1.69 (1.41–2.02) 0.385
MsgC8 22.27 (17.06–29.04) 8.59 (6.48–11.40) <0.0001
MsgC9 3.04 (2.35–3.94) 1.33 (1.15–1.52) <0.0001
TABLE 3. Geometric mean values and 95% CIs of ELISA by
Pneumocystis pneumonia (PcP) status in human immunode-
ﬁciency virus-positive (HIV+) patients from Seville for each
antigen
Antigen
Seville HIV+ PcP+
(n = 29)
Seville HIV+ PcP)
(n = 135) p
MsgA 3.19 (1.90–5.34) 3.67 (2.87–4.69) 0.629
MsgB 1.93 (1.19–3.15) 2.46 (1.92–3.14) 0.4088
MsgC1 1.15 (0.86–1.53) 1.10 (1.00–1.20) 0.676
MsgC3 1.54 (0.99–2.41) 1.72 (1.41–2.10) 0.64
MsgC8 19.41 (10.12–37.24) 7.21 (5.30–9.83) 0.0079
MsgC9 1.65 (1.02–2.65) 1.27 (1.10–1.45) 0.1536
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response to MsgC8, however, was signiﬁcantly higher in the
PcP+ population (19.41 U) than in the PcP) population
(7.21 U; p 0.0079).
Hierarchy of responses to MsgC8
We have previously shown that there is a hierarchy of reac-
tivity to each of the Msg constructs across different patient
populations in Cincinnati [25,37]. The lack of strong reactiv-
ity to many of the constructs used here precludes the assign-
ment of such a hierarchy, except for reactivity to MsgC8.
Blood donors and PcP+ patients had very similar levels of
reactivity to MsgC8 (22.27 U and 19.41 U, respectively), and
PcP) patients exhibited a lower level of response (7.21 U)
(Fig. 2). PcP+ patients showed the widest range of responses
(1–614 U), and the PcP) patients had the smallest range
(1–172 U) (data not shown). The range of values obtained
for the other Msg constructs also changed with the popula-
tion tested, with the PcP) patients consistently having the
lowest ranges of reactivity to all MsgC constructs (data not
shown).
Discussion
In our previously published work, we described the use of
recombinant fragments of Msg in probing serological reactiv-
ity of blood donors and HIV+ patients in the USA [25,37]. In
this study, we have analysed blood donors from Seville with
these constructs, and found a geographical difference in the
reactivity to three of the constructs, MsgC3, MsgC8, and
MsgC9. Spanish blood donors, as a group, exhibited signiﬁ-
cantly higher reactivity to MsgC8, and lower reactivity to
MsgC3 and MsgC9, than did blood donors from Cincinnati.
This regional difference may indicate that Msg isoform
expression is geographically controlled. Extending the analy-
sis to include a cohort of Spanish HIV+ patients shows that
those who had PcP have higher responses to MsgC8 than do
those who did not have PcP.
The level of recognition of MsgA, MsgB and MsgC1 is very
similar in blood donor populations from Cincinnati and from
Seville. This is consistent with our previous data showing no
difference in the frequency of recognition of these constructs
in western blot analysis of serological reactivity, using blood
donor samples from the USA, Haiti, South Africa, and South
Korea [24]. However, as reported here, the antibody titres
to MsgC3, MsgC8 and MsgC9 are signiﬁcantly different in
the Cincinnati and Seville blood donor populations. MsgC8,
which is recognized poorly by sera from the USA, was
recognized very strongly by the Spanish sera.
There are three potential reasons for the increased
response to MsgC8 in the Spanish sera. First, the rate of
P. jirovecii infection or colonization may be higher in Spain
than it is in the USA, with the increase in exposure to P. jiro-
vecii antigens having a boosting effect on antibody responses
to Msg. We feel that this is unlikely, as the seroprevalence
of Pneumocystis infection in Spanish children is similar to that
found in other global regions, including North America,
Africa, and northern Europe [7,10,42–44]. Second, the
expressed repertoire of antigen-speciﬁc receptors on B-cells,
T-cells and antigen-presenting cells may be different in the
Spanish and North American populations. Third, the spec-
trum of Msg molecules expressed in P. jirovecii from Spain
may be different from that expressed in midwestern USA
isolates. It is likely that both immune repertoire and Msg
repertoire play a role in the expression of Msg epitopes.
Presumably, the antibodies that we are measuring arose as a
consequence of exposure to P. jirovecii expressing MsgC8-like
molecules. This would indicate that MsgC8-like molecules
are expressed more prevalently in Spanish populations of
P. jirovecii than in American populations of the organism. Var-
iation in msg genes among different isolates of P. jirovecii has
p < 0.001
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FIG. 2. Comparison of blood donor (BD) with Pneumocystis pneu-
monia (PcP+) and without Pneumocystis pneumonia (PcP)) patient
groups, showing geometric means and 95% CIs for reactivity to
major surface glycoprotein (Msg)C8 in ELISA. Comparisons between
groups were made using ANOVA. Signiﬁcant values (p <0.05) are
shown.
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recently been shown by Kutty et al. [45], highlighting the
possibility of global differences in expressed Msg antigens.
It is unclear why the spectrum of Msg molecules
expressed by P. jirovecii would vary according to the geogra-
phical location of its host, but factors potentially affecting
such expression might include selection of antigens within
the infected host population, strain variation in P. jirovecii
between Seville and Cincinnati, and geographical factors such
as temperature, humidity, and elevation. The localized
expression of Msg molecules within a population may be
directly related to the mode of transmission. Person-to-per-
son transmission is likely to be a very important mechanism
of dissemination of P. jirovecii. However, the antigenic com-
plexity of the Msg fragments precludes their use as tools for
clearly tracking transmission of the organism.
Interestingly, there were two Msg fragments (MsgC3 and
MsgC9) that showed a signiﬁcantly higher level of reactivity
in the Cincinnati population than in the Seville population. It
is unclear whether these MsgC molecules represent antigens
with localized expression, as the difference in response to
these antigens between European and American populations
was not as great as the difference seen for MsgC8. It is pos-
sible that an isotype of MsgC that could be selectively recog-
nized in American populations does exist; however, such a
molecule is not present in our small library of Msg frag-
ments.
The hierarchy of recognition of MsgC8 showed that HIV+
PcP) patients had a signiﬁcantly lower level of reactivity than
did healthy blood donors or HIV+ PcP+ patients. Variation in
recognition of the Msg fragments according to different
patient populations has been seen before. However, the var-
iation seen in the Spanish populations is very interesting. The
high level of reactivity in the blood donors and PcP+ patients
suggests that MsgC8 is expressed during P. jirovecii exposure,
either in infection or colonization, and this drives the
immune response up. Furthermore, the higher titre of anti-
bodies in the PcP+ patient group suggests that these antibo-
dies are relevant to recovery from disease and that MsgC8
has protective epitopes in a geographical location where
expression of MsgC8 is high. The lack of a strong response
in the PcP) patients may be due to impaired immunity.
Finally, the data presented here show that MsgC clones
must be regarded as individual entities and not as generic
antigens. The isoform-speciﬁc antibodies seen in this study
underline the potential for Msg as a variant antigen that may
play a role in immune evasion. It is likely that Msg molecules
are composed of shared and unique epitopes. However, the
contribution of each type of epitope to the overall immune
reactivity to P. jirovecii and the ability to counteract P. jirovecii
infection/colonization remain unknown.
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